SynthesisBMC psychiatry2026
Efficacy and safety of non-hormonal pharmacotherapies for depressive and anxiety symptoms during the menopausal transition and postmenopause: a systematic review.
Synthesis in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-hormonal pharmacotherapies are widely used to manage depressive and anxiety symptoms in peri- and postmenopausal women, but comparative evidence across drug classes remains heterogeneous.
objectiveTo systematically evaluate the efficacy and safety of non-hormonal pharmacological interventions for depressive and anxiety symptoms during the menopausal transition and postmenopause.
methodsA systematic review of six databases and trial registries identified randomized and non-randomized studies evaluating SSRIs, SNRIs, gabapentinoids, and other pharmacotherapies. Due to substantial clinical and methodological heterogeneity, a structured Synthesis Without Meta-analysis (SWiM) approach was applied.
resultsA total of Thirty-one studies (n = 8,124 participants) were included. SNRIs showed more frequent positive effects on depressive symptoms compared with other pharmacological classes, while SSRIs demonstrated modest and variable effects. Gabapentinoids consistently improved vasomotor symptoms but showed limited and low-certainty effects on mood outcomes. Evidence for anxiety outcomes was inconsistent across all drug classes. Certainty of evidence ranged from very low to moderate.
conclusionsNon-hormonal pharmacotherapies may provide benefit for mood symptoms during the menopausal transition and postmenopause, particularly SNRIs; however, conclusions are limited by heterogeneity, indirectness, and lack of head-to-head comparative trials. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.